REPORTING FROM THSNA 2018
He acknowledged certain limitations of the study, including its single-center design, relatively small sample size, and lack of clinical endpoints. “I’d like to be able to tie this to something like reduced bleeding events,” Dr. Falsetta said. “I think that’s something we need to explore in the future.”
Dr. Falsetta reported having no financial disclosures.
SOURCE: Falsetta J et al. THSNA 2018.
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Data from a large review support use of D-dimer levels to diagnose PE without imaging.
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
